Premium
Endothelial cell biomarkers in critically ill COVID‐19 patients with encephalitis
Author(s) -
Altmayer Victor,
Ziveri Jason,
Frère Corinne,
Salem JoeElie,
Weiss Nicolas,
Cao Albert,
Marois Clémence,
Rohaut Benjamin,
Demeret Sophie,
Bourdoulous Sandrine,
Le Guennec Loic
Publication year - 2022
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.15545
Subject(s) - encephalitis , medicine , thrombomodulin , intensive care unit , viral encephalitis , cytokine , magnetic resonance imaging , encephalopathy , gastroenterology , tumor necrosis factor alpha , endothelial activation , vascular endothelial growth factor , anesthesia , immunology , inflammation , radiology , virus , platelet , thrombin , vegf receptors
COVID‐19 is associated with encephalitis in critically ill patients and endothelial dysfunction seems to contribute to this life‐threatening complication. Our objective was to determine the hallmark of endothelial activation in COVID‐19‐related encephalitis. In an observational study in intensive care unit (ICU), we compared vascular biomarkers of critically ill COVID‐19 patients with or without encephalitis. To be classified in the encephalitis group, patients had to have new onset of central neurologic symptom, and pathological findings on either brain magnetic resonance imaging (MRI) and/or electroencephalogram (EEG). Among the 32 critically ill COVID‐19 consecutive patients, 21 were categorized in the control group and 11 in the encephalitis group. Encephalitis patients had a longer ICU stay than control patients (median length [25th–75th percentile] of 52 [16–79] vs. 20.5 [11–44] days, respectively, p = 0.04). Nine‐month overall follow‐up mortality reached 21% (7/32 patients), with mortality rates in the encephalitis group and the control group of 27% and 19%, respectively. Encephalitis was associated with significant higher release of soluble endothelial activation markers (sE‐selectin, tumor necrosis factor‐α (TNF‐α), interleukin 6, placental growth factor, and thrombomodulin), but these increases were correlated with TNF‐α plasmatic levels. The hypoxia‐inducible protein angiopoietin‐like 4 (ANGPTL4) was at significantly higher levels in encephalitis patients compared to control patients ( p = 0.0099), and in contrary to the other increased factors, was not correlated with TNF‐α levels ( r = 0.2832, p = 0.1163). Our findings suggest that COVID‐19‐related encephalitis is a cytokine‐associated acute brain dysfunction. ANGPTL4 was the only elevated marker found in encephalitis patients, which was not correlated with systemic inflammation, suggesting that ANGPTL4 might be a relevant factor to predict encephalitis in critically ill COVID‐19 patients.